Pendapatan dodolan perusahaan ideayabio.com (IDYA)

The development of precision oncology through alliances with pharma behemoths carries risks evident in the sales monitoring of IDEAYA Biosciences (IDYA); currently, the current parameter is 0.04. Attracting top chemists via stock options supports innovation, yet a high concentration in early-stage assets creates binary threats to capital, necessitating a gradual expansion of the partnership portfolio to stabilize the business.

IDYA Pendapatan lan volume dodolan IDEAYA Biosciences, Inc. (04.07.2022 - 14.11.2026)

Rincian metrik komprehensif lan analitis IDEAYA Biosciences, Inc. (IDYA)

- rega lan prakiraan konsensus rega:

Rega saham IDEAYA Corp|IDYA - Bagan rega target

- rincian kapitalisasi pasar:

Nilai pasar IDEAYA Biosciences, Inc.|IDYA - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku Siji Saham IDEAYA Biosciences|IDYA - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku ideayabio.com|IDYA - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang Agregat marang Modal IDEAYA Biosciences|IDYA - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal IDEAYA Biosciences Inc|IDYA - Gunggung utang perusahaan|Rasio utang marang nilai buku IDEAYA Biosciences, Inc.|IDYA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan IDEAYA Biosciences|Rasio likuiditas perantara ideayabio.com

- data bathi lan kelipatan valuasi:

IDYA - Bathi resik|Penghasilan resik sing dikarepake IDEAYA Biosciences|IDYA - Pangali P/E|Rasio prakiraan rega marang bathi ideayabio.com|IDYA - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan IDEAYA Biosciences, Inc.|IDYA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) IDEAYA Biosciences|IDYA - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan ideayabio.com|IDYA - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham ing taun ngarep IDEAYA Biosciences

- statistik dodolan lan pendapatan perusahaan:

IDYA - Pendapatan lan volume dodolan|Dodolan mangsa ngarep perusahaan IDEAYA Corp|IDYA - Multiplikator P/S|Kapitalisasi marang prakiraan pendapatan IDEAYA Biosciences, Inc.

Ringkesan analisis perusahaan:IDEAYA Corp IDYA

Sales volume measures the aggregate cash flow from core operations, allowing investors to filter out market noise and assess the actual expansion of the business. Analyzing the sales history of IDEAYA Biosciences (IDYA) reveals how the monetization of partnerships with pharma behemoths and the success of darovasertib and IDE397 are transforming the company's R&D potential into sustainable financial growth.

Perusahaan pesaing

Pendapatan lan volume dodolan Genmab Corp|Pendapatan perusahaan Exelixis, Inc. (EXEL)|NUVL (nuvalent.com) - Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan KYMR (Kymera)|Total volume dodolan perusahaan Enliven Therapeutics Inc|ORIC Pharma - Pendapatan lan volume dodolan|Total pendapatan perusahaan Relay Corp|NRIX (Nurix Therapeutics) - Dodolan perusahaan|TYRA: Total dodolan perusahaan|VSTM (Verastem) - Pendapatan lan volume dodolan|Total pendapatan perusahaan Monte Rosa Therapeutics Inc GLUE|Pendapatan lan volume dodolan CGEM|Immuneering Corp. - Volume dodolan perusahaan|C4 Therapeutics, Inc. - Dodolan perusahaan|Pendapatan dodolan perusahaan BDTX|RPTX: Dodolan perusahaan|PMV Pharmaceuticals Inc. - Total dodolan perusahaan|KPTI: Pendapatan lan volume dodolan|Propanc Biopharma - Pendapatan dodolan perusahaan|BGMS (Bio Green Med Solution Inc) - Pendapatan lan volume dodolan|Total pendapatan perusahaan Aadi Bio AADI|Pendapatan perusahaan Aileron Therapeutics (ALRN)|BPMC (blueprintmedicines.com) - Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan GLYC (GlycoMimetics)|Pendapatan lan volume dodolan SpringWorks Therapeutics, Inc SWTX